Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from the Benelux countries Belgium, Luxembourg and The Netherlands or involving organisations from these countries.

Total search results: 1358 | Ordered by Date (descending)
next pagenext page 1 2 3 4 5 6 7 8 9 10 11 12 13 14  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Ona Therapeutics–Fund+: investment, 202006 financing round Series A totalling €30m incl new investor Fund+ 2020-06-16
Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m 2020-06-16
Ona Therapeutics–Ysios Capital: investment, 202006 financing round Series A totalling €30m incl new investor Ysios Capital 2020-06-16
JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV 2020-06-12
Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance 2020-06-10
Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM 2020-06-10
Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF 2020-06-10
Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV 2020-06-10
Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab 2020-06-10
Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor JnJ Innovation 2020-06-10
Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep 2020-06-10
Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al 2020-06-10
The Clinical Company–Excelya: investment, 202007 acquisition 2020-06-07
Hyloris Pharmaceuticals–SEVERAL: investment, 202006 IPO $65.2m at $12/share at Euronext Brussels 2020-06-03
Prilenia–Forbion: investment, 202006 financing round Series A totalling $62.5m incl new + lead investor Forbion 2020-06-03
Prilenia–Genworks 2: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Genworks 2 2020-06-03
Prilenia–Instinctif Partners: public relations, 202006 service existent by Instinctif 2020-06-03
Prilenia–Morningside: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Morningside Venture Investments 2020-06-03
Prilenia–Sectoral Asset Management: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Sectoral Asset Management 2020-06-03
Prilenia–SEVERAL: investment, 202006 financing round Series A $62.5m led by new investor Forbion 2020-06-03
Prilenia–Talisman Capital Partners: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Talisman Capital Partners 2020-06-03
Kumovis–Ffilipa Venture Capital: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor Ffilipa Venture Capital 2020-05-27
Kumovis–High-Tech Gründerfonds: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor HTGF 2020-05-27
Kumovis–SEVERAL: investment, 202005 financing round Series A €3.6m led by Renolit + Solvay Ventures 2020-05-27
Kumovis–Solvay: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Solvay Ventures 2020-05-27
Argenx–SEVERAL: investment, 202005 global offering $862.5 via ADS offering in US + private placement in Europe 2020-05-26
Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon 2020-05-16
OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader 2020-05-16
JnJ–Lava Therapeutics: bispecific antibodies, 202005– collab €na research + license agreem for bispecfic gamma-delta T-cell engagers Janssen Biotech 2020-05-15
Polyganics–EU (govt): grant, 202005 EFRO grant €1.2m for clinical development of Liver + Pancreas Sealant Patch 2020-05-13
Polyganics–Instinctif Partners: public relations, 202005 service existent by Instinctif 2020-05-13
Hyloris Pharmaceuticals–Consilium: public relations, 202004 service existent by CSC 2020-04-30
Hyloris Pharmaceuticals–SEVERAL: investment, 202004 financing round €15m incl Scorpiaux + Noshaq + Staffelberg Investments + Nomainvest 2020-04-30
Bone Therapeutics–SEVERAL: credit, 202004– bridge loans €4.75m 2020-04-29
Bone Therapeutics–SEVERAL: credit, 202004– fleixble convertibe bonds €4.99m 2020-04-29
Bone Therapeutics–SEVERAL: investment, 202004 private equity placement €1.26m in form of immediate conversion of convertible bonds 2020-04-29
Kurma–EU (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor EIF 2020-04-29
Kurma–Institut Pasteur: investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor Pasteur Institute 2020-04-29
Kurma–North Rhine-Westphalia (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor NRW.BANK 2020-04-29
Kurma–SEVERAL: investment, 202004 final closing of Kurma Biofund III with €160m 2020-04-29
Robocath–SEVERAL: investment, 202004 financing round Series C €40m led by MicroPort Scientific 2020-04-29
Genedata–Cergentis: genomic software tools, –202004 collab developm of Genedata Selector s/w for automating TLA data analysis workflow 2020-04-28
Biotecon–EW Group: investment, 202004 acquisition of Biotecon Diagnostics GmbH by BioChek BV 2020-04-23
FoRx Therapeutics–Life Sciences Partners: investment, 202004 seed financing round totalling €10m incl co-investor LSP 2020-04-22
FoRx Therapeutics–Merck (DE): investment, 202004 seed financing round totalling €10m incl co-lead investor M Ventures 2020-04-22
FoRx Therapeutics–SEVERAL: investment, 202004 seed financing round €10m co-led by M Ventures + Novartis Venture Fund + Omega Funds 2020-04-22
Galapagos–Ryvu Therapeutics: anti-inflammatory drugs, 202004– collab r+d small molecules against new target w excl license option for Galapagos 2020-04-16
Centogene–FTI Consulting: public relations, 202004 service existent by FTI Consulting 2020-04-15
Gadeta–Optimum Strategic Communications: public relations, 202004 service existent by Optimum 2020-04-07
Amgen–NewAmsterdam Pharma: investment, 202004 acquisition €na of Dezima Pharma from Amgen incl all rights for obicetrapib (TA-8995) 2020-04-01
iTeos Therapeutics–6 Dimensions Capital: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor 6 Dimensions Capital 2020-04-01
iTeos Therapeutics–Belgium (govt): investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor SFPI 2020-04-01
iTeos Therapeutics–Curative Ventures: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor Curative Ventures 2020-04-01
iTeos Therapeutics–Fund+: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor Fund+ 2020-04-01
iTeos Therapeutics–HBM: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor HBM Partners 2020-04-01
iTeos Therapeutics–Invus Group: investment, 202004 financing round Series B2 totalling $125m incl new + co-investor Invus 2020-04-01
iTeos Therapeutics–Janus Henderson: investment, 202004 financing round Series B2 totalling $125m incl new + co-investor Janus Henderson Investors 2020-04-01
iTeos Therapeutics–MPM Capital: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor MPM Capital 2020-04-01
iTeos Therapeutics–RA Capital: investment, 202004 financing round Series B2 totalling $125m incl new + co-lead investor RA Capital Management 2020-04-01
iTeos Therapeutics–RTW Investments: investment, 202004 financing round Series B2 totalling $125m incl new + co-investor RTW Investments 2020-04-01
iTeos Therapeutics–SEVERAL: investment, 202004 financing round Series B2 $125m co-led by RA Capital Management + Boxer Capital 2020-04-01
iTeos Therapeutics–Tavistock: investment, 202004 financing round Series B2 totalling $125m incl new + co-lead investor Boxer Capital 2020-04-01
iTeos Therapeutics–UCLouvain: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor VIVES Louvain Technology Fund 2020-04-01
iTeos Therapeutics–Wallonia (govt): investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor SRIW 2020-04-01
AM-Pharma–Cowen: investment, 202003 equity investment €23m ($25.5m) mainly from Cowen Healthcare Investments 2020-03-31
AM-Pharma–EU (govt): credit, 202003– finance facility €24m from EIB 2020-03-31
Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments 2020-03-31
Immatics–Arya Sciences: investment, 202003 reverse merger resulting in Nasdaq-listing of Immatics + $148m cash held by Arya 2020-03-17
NanoSyrinx–BioCity (GB): investment, 202003–202009 pre-seed financing round incl co-investor BioCity Group 2020-03-16
NanoSyrinx–Merck (DE): investment, 202003–202009 pre-seed financing round incl lead investor M Ventures 2020-03-16
NanoSyrinx–Midven: investment, 202003–202009 pre-seed financing round incl co-investor UKI2S Fund 2020-03-16
NanoSyrinx–SEVERAL: investment, 202003–202009 pre-seed financing round led by M Ventures + incl BioCity + UKI2S Fund 2020-03-16
Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS 2020-03-10
Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF 2020-03-10
Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical 2020-03-10
Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF 2020-03-10
Bone Therapeutics–Image Box: public relations, 202003– supply service by Image Box PR 2020-03-06
Biotalys–Novalis LifeSciences: investment, 202003 financing round Series C 2nd closing totalling €10m incl new investor Novalis LifeSciences 2020-03-05
Biotalys–SEVERAL: investment, 202003 financing round Series C €10m 2nd closing bringing total Series C to €45m 2020-03-05
Qiagen–Barclays: financial services, 202003 supply service Barclays Bank plc is financial advisor w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–De Brauw Blackstone Westbroek: legal services, 202003 supply service De Brauw BW NV is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Goldman Sachs: financial services, 202003 supply service Goldman Sachs Intl is lead financial advisor w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Linklaters: legal services, 202003 supply service Linklaters LLP is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Mintz Levin Cohn: legal services, 202003 supply service Mintz Levin Cohn FGP is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Thermo Fisher: investment, 202003–202008 acquisition €9.14b cash tender offer at €39/share later raised to €43 NOT ACCEPTED 2020-03-03
Thermo Fisher–JPMorgan Chase: financial services, 202003 supply service JP Morgan Securities LLC is financial advisor w regard to Qiagen acquisition 2020-03-03
Thermo Fisher–Morgan Stanley: financial services, 202003 supply service Morgan Stanley & Co LLC is financial advisor w regard to Qiagen acquisition 2020-03-03
Thermo Fisher–Wachtell Lipton: legal services, 202003 legal council to Thermo Fisher with regard to acquisition of Qiagen 2020-03-03
Glycom–DSM: investment, 202002 acquisition of Glycom A/S by DSM for enterprise value of €765m 2020-02-21
OncoDNA–Belgium (govt): investment, 202002 financing round Series B totalling €19m incl significant support from co-investor SFPI-FPIM 2020-02-14
OncoDNA–SEVERAL: investment, 202002 financing round Series B €19m co-led by Vesalius Biocapital III + Swisscanto Invest 2020-02-14
OncoDNA–Vesalius Biocapital: investment, 202002 financing round Series B totalling €19m incl co-lead investor Vesalius Biocapital III 2020-02-14
OncoDNA–Zürcher Kantonalbank: investment, 202002 financing round Series B totalling €19m incl co-lead investor Swisscanto Invest by ZKB 2020-02-14
Azafaros–BioGeneration Ventures: investment, 202002 financing round Series A totalling €25m incl existing + co-investor BiGV 2020-02-06
Azafaros–BioMedPartners: investment, 202002 financing round Series A totalling €25m incl co-investor BioMedPartners 2020-02-06
Azafaros–Forbion: investment, 202002 financing round Series A totalling €25m incl lead investor Forbion 2020-02-06
Azafaros–SEVERAL: investment, 202002 financing round Series A €25m led by Forbion with participation from BioMedPartners + BGV 2020-02-06
Azafaros–Trophic Communications: public relations, 202002 service existent by Trophic Communications 2020-02-06
Catalent–SEVERAL: investment, 202002 underwritten public offering $500m+$75m with approx $330m intented to finance MaSTherCell acquisition 2020-02-03
Orgenesis–Catalent: investment, 202002 acquisition $315m in cash of MaSTherCell Global Inc from Great Point Partners + SFPI-FPIM + Orgenesis Inc 2020-02-03
next pagenext page 1 2 3 4 5 6 7 8 9 10 11 12 13 14  next pagenext page



Advertisement

Picture [iito] Made Without Love 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px

» top